When temozolomide alone fails: Adding procarbazine in salvage therapy of glioma

Canadian Journal of Neurological Sciences

Volumn 35, Issue 2, 2008, Pages 192-197

  Huang, Fleur ^a   Kavan, Petr ^a   Guiot, Marie Christine ^a   Markovic, Yelena ^a   Roberge, David ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB; PROCARBAZINE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; GLIOMA; HISTOLOGY; HUMAN; LYMPHOCYTOPENIA; MALE; METHYLATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PRIORITY JOURNAL; RECURRENT DISEASE; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 45149125163     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100008623     Document Type: Article

References (22)

1. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, et al. Changing paradigms - an update on the multidisciplinary management of malignant glioma. Oncologist. 2006 Feb;11(2):165-80.
2. Brandes AA, Tosoni A, Basso U, Reni M, Valduga F, Monfardini S, et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Uncol. 2004 Dec 1;22(23):4779-86.
3. Rabik CA, Njoku MC, Dolan ME. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev. 2006 Jun;32(4):261-76.
4. Brandes AA, Reni M. Treatment options for recurrent glioblastoma. PCNSM2- Perspectives in central nervous system malignancies. Budapest, Hungary; 2006.
5. Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-oncol. 2002 Jan;4(1):39-43.
6. Tosoni A, Cavallo G, Ermani M, Scopece L, Franceschi E, Ghimenton C, et al. Is protracted low-dose temozolomide feasible in glioma patients? Neurology. 2006 Feb 14;66(3):427-9.
7. Berrocal A, Perez-Segura P, Gil M, Balana C, Yaya-Tur R, Yaya-Tur R, et al. Phase II study of extended schedule temozolomide in refractory gliomas. J Clin Oncol. 2006;24(18S):1516.
8. Vera K, Djafari L, Faivre S, Guillamo JS, Djazouli K, Osorio M, et al. Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. Ann Oncol. 2004 Jan;15(1):161-71.
9. Koch D, Wick W. Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years. J Neurooncol. 2006 Apr;77(2):219-20.
10. Spence AM, Kiem HP, Partap S, Schuetze S, Silber JR, Peterson RA. Complications of a temozolomide overdose: a case report. J Neurooncol. 2006 Oct;80(1):57-61.
11. Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Salvage temozolomide for prior temozolomide responders. Cancer. 2005 Dec 1;104(11):2473-6.
12. Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, et al. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol. 2006 Oct;80(1):83-90.
13. Raizer JJ, Abrey LE, Wen P, Cloughesy T, Robins IA, Fine HA, et al. A phase II trial of erlotinib (OSI-774) in patients with recurrent malignant gliomas not on EIAEDs. 2004 ASCO Annual Meeting; 2004; New-Orleans, Louisiana: J Clin Oncol. 2004, p. 1502.
14. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000 Nov 9;343(19):1350-4.
15. Bollag W. The tumor-inhibitory effects of the methylhydrazine derivative Ro 4-6467/1 (Nsc-77213). Cancer Chemother Rep. 1963 Dec;33:1-4.
16. Goodman & Gilman's The pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006.
17. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group. Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. J Neurosurg. 1981 Jul; 55(1):27-31.
18. Rodriguez LA, Prados M, Silver P, Levin VA. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer. 1989 Dec 15;64(12):2420-3.
19. Newton HB, Junck L, Bromberg J, Page MA, Greenberg HS. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology. 1990 Nov;40(11):1743-6.
20. Grossman SA, Carson KA, Batchelor TT, Lesser G, Mikkelsen T, Alavi JB, et al. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. Clin Cancer Res. 2006 Sep 1;12(17):5174-81.
21. Newlands ES, Foster T, Zaknoen S. Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Br J Cancer. 2003 Jul 21;89(2):248-51.
22. DeVita VT Jr, Hellman S, Rosenberg S, editors. Cancer principles & practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.